abstract |
The subject invention provides materials and methods for efficient, specific reduction or elimination of unwanted mRNA. These materials and methods can be used in therapies for retinal diseases. In one embodiment, ribozymes which degrade mutant rod opsin mRNA are used to treat retinitis pigmentosa or diabetic retinopathy. In a further embodiment, ribozymes which cleave RNAs involved in nitric oxide activity are used to treat blood-retinal dysfonction. The preferred targets include VEGF, eNOS, and iNOS. |